Drug Insights

Is Eptinezumab approved by the FDA?

27 June 2024
3 min read

Yes, Eptinezumab, marketed under the brand name Vyepti, is FDA approved. The U.S. Food and Drug Administration (FDA) approved Eptinezumab on February 21, 2020. This approval provides a new option for the preventative treatment of migraine in adults, offering an intravenous solution for those who suffer from frequent migraine attacks.

What is Eptinezumab?

Eptinezumab is a medication used to prevent migraine headaches in adults. It belongs to a class of drugs known as CGRP (calcitonin gene-related peptide) inhibitors, which work by targeting and inhibiting the activity of CGRP, a molecule involved in migraine attacks.

Key Points:

  • Brand Name: Vyepti
  • Dosage Form: Intravenous solution (100 mg/mL)
  • Administration: Given as an infusion into a vein by a healthcare provider, typically once every three months.

Usage and Administration

Eptinezumab is administered as an intravenous (IV) infusion. The initial dose is usually 100 mg, and it can be increased to 300 mg depending on the patient's response and healthcare provider's recommendation. The infusion process takes at least 30 minutes to complete and is performed once every three months.

Dosing Information:

  • Initial Dose: 100 mg IV infusion every three months
  • Maintenance Dose: 100 mg or 300 mg IV infusion every three months, based on patient needs

Side Effects

Common side effects of Eptinezumab include:

  • Stuffy nose
  • Throat irritation
  • Allergic reactions such as rash, hives, and redness or swelling of the face, lips, tongue, or throat

Severe side effects may occur during the injection, such as feeling warm, itchy, or light-headed. Immediate medical help is necessary if any signs of a severe allergic reaction occur.

Warnings and Precautions

Before starting treatment with Eptinezumab, patients should inform their doctor about any medical conditions or allergies they have, as well as all medications they are currently taking. This is crucial to avoid potential drug interactions and ensure the safety and efficacy of the treatment.

Contraindications:

  • Allergy to Eptinezumab, polysorbate 80, or sorbitol

Conclusion

Eptinezumab (Vyepti) is an FDA-approved medication for the preventative treatment of migraines in adults, providing an effective option for those seeking to reduce the frequency and severity of migraine attacks. Approved on February 21, 2020, Eptinezumab is administered via IV infusion every three months, offering a promising treatment for chronic migraine sufferers.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

DA-1726 Outperforms Survodutide in Pre-Clinical Weight Reduction and Health Metrics
Latest Hotspot
3 min read
DA-1726 Outperforms Survodutide in Pre-Clinical Weight Reduction and Health Metrics
27 June 2024
In pre-clinical models, DA-1726 from NeuroBo Pharmaceuticals outperformed Survodutide in weight reduction, maintaining lean body mass, and lowering lipid levels.
Read →
Is Palforzia approved by the FDA?
Drug Insights
3 min read
Is Palforzia approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) approved Palforzia on January 31, 2020.
Read →
Sun Pharma's GL0034 Shows Promising Weight Loss in Obesity at ADA's 84th Session
Latest Hotspot
3 min read
Sun Pharma's GL0034 Shows Promising Weight Loss in Obesity at ADA's 84th Session
27 June 2024
Sun Pharma's GL0034 (Utreglutide) Showcases Remarkable Weight Loss and Metabolic Improvements in Obesity at ADA's 84th Session.
Read →
Is Trijardy XR approved by the FDA?
Drug Insights
3 min read
Is Trijardy XR approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) approved Trijardy XR on January 27, 2020, for the treatment of type 2 diabetes in adults.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.